Table 2 Prognostic factors of survival in univariate analyses
HR (95% CI) | P value | |
|---|---|---|
Overall survival | ||
Disease stage | 1.45 (1.01–2.06) | 0.041 |
T stage | 1.36 (0.87–2.13) | 0.184 |
N stage | 1.48 (1.06–2.05) | 0.021 |
Max. tumor size | 1.01 (1.00–1.03) | 0.031 |
Concurrent chemotherapy | 1.50 (0.66–3.42) | 0.330 |
Age | 1.02 (0.99–1.06) | 0.217 |
Sex | 1.27 (0.60–2.70) | 0.532 |
Disease-free survival | ||
Disease stage | 1.56 (1.03–2.38) | 0.037 |
T stage | 1.05 (0.64–1.78) | 0.868 |
N stage | 1.66 (1.14–2.42) | 0.009 |
Max. tumor size | 1.00 (0.98–1.02) | 0.937 |
Concurrent chemotherapy | 1.17 (0.47–2.93) | 0.739 |
Age | 1.01 (0.97–1.06) | 0.509 |
Sex | 1.66 (0.69–3.98) | 0.259 |
Locoregional control | ||
Disease stage | 1.62 (1.04–2.53) | 0.033 |
T stage | 1.17 (0.67–2.03) | 0.586 |
N stage | 1.68 (1.13–2.51) | 0.010 |
Max. tumor size | 1.00 (0.98–1.02) | 0.725 |
Concurrent chemotherapy | 1.26 (0.47–3.35) | 0.650 |
Age | 1.01 (0.97–1.06) | 0.608 |
Sex | 1.67 (0.66–4.20) | 0.278 |
Colostomy free survival | ||
Disease stage | 1.48 (0.95–2.30) | 0.082 |
T stage | 1.30 (0.74–2.30) | 0.358 |
N stage | 1.62 (1.07–2.46) | 0.022 |
Max. tumor size | 1.01 (0.99–1.03) | 0.227 |
Concurrent chemotherapy | 1.26 (0.47–3.36) | 0.644 |
Age | 0.99 (0.95–1.03) | 0.533 |
Sex | 1.04 (0.40–2.69) | 0.931 |